Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts. (Funded by MedImmune [a member of the AstraZeneca Group] and Amgen; PATHWAY ClinicalTrials.gov number, NCT02054130.)

中文翻译：

---

成人哮喘不受控制的Tezepelumab

在接受长效β-受体激动剂和中至高剂量吸入糖皮质激素治疗的患者中，接受替泽贝单抗治疗的患者的临床显着哮喘急性发作率低于接受安慰剂的患者，而与基线嗜酸性粒细胞计数无关。（由MedImmune [阿斯利康集团的成员]和Amgen资助； PATHWAY ClinicalTrials.gov编号，NCT02054130。）